Peptide Library · checked July 17, 2026

Mazdutide

Mazdutide has a positive published phase 3 weight-loss trial in Chinese adults. That is substantial human evidence. It is still not FDA approval, and a real trial does not authenticate an unrelated United States product carrying the same name.

SupportedMore than one relevant human study, with material limits still present.How labels work →

TL;DR

The lowdown

Four answers first. The source record follows.

01 · Identity

What is it?

Dual GLP-1 and glucagon receptor agonist

02 · Human evidence

What do humans show?

Randomized phase 3 obesity trial in China

03 · U.S. status

Where does FDA stand?

No FDA-approved mazdutide product

04 · Risks

What is known—and not?

The published phase 3 trial reported gastrointestinal adverse events most often. Long-term risk characterization, U.S. labeling, contraindications, and product-quality controls cannot be inferred for an unapproved online product.

U.S. status · July 17, 2026

Approval, compounding, product, sport.

FDA approval: No FDA-approved mazdutide product; FDA has cited online U.S.
U.S. federal record: No FDA-approved mazdutide product; FDA has cited online U.S. products as unapproved new drugs
Product identity: No separate finished-product identity conclusion is recorded in this reviewed source.
Sport: No WADA status recorded in the reviewed source.

This reports the dated federal and sport record. It does not determine whether a particular product or transaction complies with state or federal law, and it is not legal advice.

What it is

Mazdutide is an investigational dual agonist that acts at GLP-1 and glucagon receptors. Its development program includes obesity and type 2 diabetes research.

The clean way to describe it is milestone by milestone: a substance can have positive human trials, complete phase 3 research in one jurisdiction, and still lack an FDA-approved U.S. drug product.

What humans actually show

GLORY-1: A phase 3 trial randomized 610 adults in China to mazdutide, placebo, or one of two studied dose groups for 48 weeks.
Week 48: Mean body-weight change was −11.00% in one mazdutide group, −14.01% in the other, and +0.30% with placebo.
Larger reductions: At least 15% weight loss occurred in 35.7%, 49.5%, and 2.0% of those groups, respectively.
Adverse events: Gastrointestinal events were reported most often and were described as mostly mild to moderate.
Transfer limit: These results belong to the identified trial material, trial population, and study conditions. They do not establish the contents or performance of an unrelated product.

FDA and U.S. status

PepCurrent found no FDA-approved mazdutide drug product in the United States. FDA warning letters have described mazdutide products offered online in the United States as unapproved new drugs.

The distinction is not semantic. FDA approval evaluates a defined application and product, including manufacturing and labeling. A paper reporting a positive trial cannot perform that product-level review.

Risks and warning limits

PepCurrent does not provide dosing, sourcing, switching, or personalized treatment advice.

What would change this answer

Any U.S. clinical development or FDA application
Longer-term and broader-population results
Full cardiovascular and safety evidence
Online claims that omit the study’s country, population, and product-identity boundary

Sources and records

Educational journalism only; not medical advice. We do not evaluate individual products or link vendors.

What changed

Added the published GLORY-1 phase 3 results and a dated U.S. status check.

What would change our answer

An FDA application or approval action would change the U.S. status. Longer-term or broader-population trials could change confidence for defined outcomes.

Version history · 1 entry

v1 · 2026-07-17Initial source-verified evidence and status record.Source ↗

Boundary: PepCurrent explains public evidence and regulatory records. We do not evaluate individual products, recommend use, name vendors, or provide protocols.